Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
INCB13739 · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| INCB13739 | DRUG | - |
Inclusion Criteria: * Male and female subjects between 18 years and 65 years of age. * BMI between 30 and 42 kg/m2, inclusive. * FPG \<126 mg/dL Exclusion Criteria: * Meet criteria for diagnosis of diabetes mellitus at the screening evaluation, female subjects with a history of gestational diabet...
INCB13739 is an investigational small molecule being developed for insulin resistance, a metabolic condition. It was studied in a Phase 1 clinical trial in obese people predisposed to diabetes, with the aim of evaluating its effect on cortisone reducing enzyme activity. The drug is not approved and remains in clinical development.
INCB13739 is developed by Incyte Corporation, a biopharmaceutical company traded on the NASDAQ under the ticker INCY. Incyte is conducting clinical research on this investigational small molecule for the treatment of insulin resistance.
INCB13739 is in Phase 1 clinical development. It has completed one Phase 1 trial, which was a randomized, double-blind, uncontrolled study. The drug is investigational and has not been approved by regulatory authorities.
INCB13739 has one completed clinical trial, identified as NCT00398619. The study, titled 'A Study of the Effect of INCB013739 on Cortisone Reducing Enzyme Activity in Obese People Predisposed to Diabetes,' was a Phase 1 trial conducted in the United States in adults with insulin resistance and obesity.
Yes, INCB13739 is also known as INCB013739. The clinical trial NCT00398619 uses the name INCB013739 in its title, while the drug is referred to as INCB13739 in other contexts. Both names refer to the same investigational small molecule.